Ohio State University Comprehensive Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Ohio State University Comprehensive Cancer Center sits in the top decile of US sponsors by registered trial count (#105 of 15,742 sponsors by registered trial count).
Ohio State University Comprehensive Cancer Center: 341 sponsored US clinical trials, 77 recruiting.
Ohio State University Comprehensive Cancer Center sponsors 341 registered US clinical trials on ClinicalTrials.gov, 77 of them currently recruiting, and 206 completed. 5 of these trials are in Phase 3-4 (later-stage) and 116 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Anatomic Stage II Breast Cancer AJCC v8, with 10 trials.
Top-decile sponsor footprint
Ohio State University Comprehensive Cancer Center ranks in the top decile of sponsors by registered trial count (#105 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
206 of 217 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (94.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
341 total, page 7 of 7
Freeze-Dried Black Raspberries in Preventing Oral Cancer Recurrence in High At-Risk Appalachian Patients Oral Cancer Survivors
NCT01504932
Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma
NCT00418496
Ohio Patient Navigator Research Program
NCT01569672
Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00124644
Pemetrexed Chemotherapy in Poor-Risk Patients With Advanced Head and Neck Cancer
NCT00293579
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma
NCT01462773
Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT00267696
OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer
NCT00230126
Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer
NCT00201864
Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT00143065
Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary
NCT00201734
Community Awareness, Resources and Education (CARE I): Project 3
NCT02113514
Low Fat Versus Protein Sparing Diet for Weight Loss & Impact on Biomarkers Associated With Breast Cancer Risk
NCT01559194
Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma
NCT00362570
Community Awareness Resources and Education - Project 1
NCT01172561
Identification of Novel Genetic Factors That Contribute to Risk for Breast Cancer
NCT00276120
Contrast of Buffered Vs. Unbuffered Lidocaine in Bone Marrow Biopsies
NCT00456872
Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma
NCT00201877
A Phase II Study of Clofarabine in Patients With Aggressive Non-Hodgkin's Lymphoma
NCT00201669
Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide in Axillary Node-Positive Breast Cancer
NCT00201708
Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases
NCT00362817
Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma
NCT00201695
2 Phase Comparison of Pre-operative CT and PET Images for Metastatic Colorectal Cancer
NCT01821105
CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas
NCT00323323
Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation
NCT00201799
Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer
NCT00201773
Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease
NCT00201786
Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer
NCT00061906
Nutritional Supplements & Complementary/Alternative Medicine by Prostate & Breast Cancer Patients
NCT01823549
Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia
NCT00201721
Prostate Biomarkers in Men Consuming Tomato Products
NCT02292524
FR901228 in Treating Patients With Hematologic Cancer
NCT00024180
Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer
NCT00201747
Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma
NCT00201838
PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors
NCT00017199
Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors
NCT00201812
SU5416, Irinotecan, and Cisplatin in Treating Patients With Advanced Solid Tumors
NCT00006000
Chloroquinoxaline Sulfonamide in Treating Patients With Stage IV Colorectal Cancer
NCT00005864
Oxaliplatin in Treating Patients With Advanced Head and Neck Cancer
NCT00005035
Pyrazoloacridine in Treating Women With Refractory Metastatic Breast Cancer
NCT00003041
Stress and Immunity Breast Cancer Project
NCT03578627
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 57 |
| Phase 2 | 59 |
| Phase 3 | 1 |
| Phase 4 | 4 |
Therapeutic Areas
What is open in the Ohio State University Comprehensive Cancer Center pipeline
77 recruiting of 341 indexed (23% open); 206 completed (60%).
Phase mix: 5 late (III/IV) vs 116 early (I/II) (early-phase heavy).
Top condition: Anatomic Stage II Breast Cancer AJCC v8 (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Ohio State University Comprehensive Cancer Center: open-pipeline peers nationwide
Peers matched on 341 registered trials and 23% open enrollment, not the therapeutic-area sidebar.
Ohio State University Comprehensive Cancer Center sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 341 trials (± recruiting share)
- Children's Oncology Group · 342 trials · 10% recruiting
- National Institute of Mental Health (NIMH) · 343 trials · 12% recruiting
- Cedars-Sinai Medical Center · 339 trials · 21% recruiting
- National Institutes of Health Clinical Center (CC) · 338 trials · 7% recruiting
Sponsors near 23% open enrollment (± trial volume)
- University of Delaware · 23% recruiting · 106 trials
- University of Virginia · 22% recruiting · 449 trials
- University of Kansas Medical Center · 23% recruiting · 408 trials
- University of Oklahoma · 22% recruiting · 358 trials
Related
What to do with this Ohio State University Comprehensive Cancer Center page
341 registered trials is a research-attention snapshot, not an endorsement of Ohio State University Comprehensive Cancer Center or any single study.
- 77 of Ohio State University Comprehensive Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Anatomic Stage II Breast Cancer AJCC v8 is the condition Ohio State University Comprehensive Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Anatomic Stage II Breast Cancer AJCC v8 trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Ohio State University Comprehensive Cancer Center pipeline card: 341 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.